Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for an ongoing Phase 2/3 study comparing Telisotuzumab Adizutecan to standard of care in adults with EGFR-mutated locally advanced or meta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Telisotuzumab Adizutecan (Telisotuzumab Adizutecan)

Snippet

Sponsor: AbbVie | Conditions: Non-Small Cell Lung Cancer | Phase 2, Phase 3 | Status: RECRUITING